

2019 ESVM – IUA – CEVF Congress *Industry Symposia*

Thursday, 10th of October, Kosovel Hall

13:00 – 14:00

Bayer

Title: Improving outcomes in patients with lower extremity PAD in the new era of dual pathway inhibition

Chair: Marianne Brodmann & Aleš Blinc

Faculty: Sigrid Nikol, Jill Belch

Objectives: To increase awareness of the availability of the DPI regimen in a patient population that needs safe and effective treatments.

To discuss the implications of the availability of the DPI regimen in daily clinical practice, with a focus on claudicant patients.

Time	Topic	Presenter
13:00 – 13:05	Welcome and Introduction	Aleš Blinc
13:05 – 13:20	The lack of effective treatments in patients with PAD: how can the COMPASS data change the current standard of care?	Marianne Brodmann
13:20 – 13:35	Clinical Cases	Sigrid Nikol and Jill Belch
13:35 – 13:50	Discussion: Clinical cases in the context of the COMPASS data and availability of the DPI regimen	All
13:50 – 14:00	Q&As and Close	All / Marianne Brodmann

Friday 11th of October, M1 Hall

13:00-14:45 *Lunch*

Sanofi

Implication of cardiovascular risk reduction with PCSK9 inhibitors: Focus on ODYSSEY OUTCOMES

How will the new PCSK9i cardiovascular outcomes trial evidence change the landscape of CV prevention?

ALEŠ BLINC (Slovenia)

Translating the PCSK9i cardiovascular outcomes trial data in very high risk patients to clinical practice

MISLAV VRSALOVIĆ (Croatia)

Kosovel Hall

18:00-18:45

Pfizer

Advanced venous thromboembolism treatment

Chairman: TJAŠA VIŽINTIN CUDERMAN (Slovenia)

Challenges in the treatment and prevention of venous thromboembolism

CECILIA BECATTINI (Italy)

Use of DOACs in patients with venous thromboembolism - data from Ljubljana registry

GREGOR TRATAR (Slovenia)